← GLP-1 receptor agonists × glycemic control

TrialJournal of diabetes investigation2016

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT01512108. Its numbers are set against the trial’s posted results below.

  • Pretrial OAD in combination with liraglutide 0.9 mg/daylooks good hereLower long-term blood sugar, lower fasting blood sugar.Randomised, small.

What the trial testedrandomised · 360 people · 2016

Randomised vs pretrial OAD in combination with an additional OAD

Probably lowered fasting blood sugar

−5.47mg/dL−10.8 to −0.10

pretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD

As reported

difference −5.47 mg/dL, 95% CI −10.8 to −0.10 · the paper's word: fasting plasma glucose levels

Randomised vs pretrial OAD in combination with an additional OAD

Probably lowered long-term blood sugar

Doesn’t vote: same as the registry's posted result, which counts instead

−0.27percentage points−0.44 to −0.09

pretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD

As reported

difference −0.27 %, 95% CI −0.44 to −0.09 · the paper's word: glycosylated hemoglobin

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −0.27 (−0.44 to −0.09)Posted difference −0.27 (−0.44 to −0.09), p = 0.0026Change in HbA1c From Baseline to Week 52

Who was studied, and how

363people in the A 52-week, Multi-centre, Open-labelled, Randomised trial, from 2012
360of them with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

pretrial OAD in combination with liraglutide 0.9 mg/day
pretrial OAD in combination with an additional OAD

Probably lowered long-term blood sugar−0.27

Probably lowered fasting blood sugar−5.47

randomised

the abstract, start to end

… [estimated mean treatment difference -0.27% (95% confidence interval (CI) -0.44, -0.09; P = 0.0026)]; reductions in mean fasting plasma glucose levels were also greater with liraglutide [estimated mean difference -5.47 mg/dL (-0.30 mmol/L; 95% CI: …

← favours treatmentfavours comparator →
could be chance
Glycosylated hemoglobinpretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD
−0.27−0.44 to −0.09
Fasting plasma glucose levelspretrial OAD in combination with liraglutide 0.9 mg/day vs pretrial OAD in combination with an additional OAD
−5.47−10.8 to −0.10
GLP-1 receptor agonistsGlycemic control
1 / 5

16 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01512108phase 3363 enrolled2012this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 26816604